These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 9754702)

  • 1. Reduced striatal dopaminergic innervation shown by IPT and SPECT in patients under neuroleptic treatment: need for levodopa therapy?
    Schwarz J; Scherer J; Trenkwalder C; Mozley PD; Tatsch K
    Psychiatry Res; 1998 Jul; 83(1):23-8. PubMed ID: 9754702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Striatal dopamine transporter binding in early to moderately advanced Parkinson's disease: monitoring of disease progression over 2 years.
    Chouker M; Tatsch K; Linke R; Pogarell O; Hahn K; Schwarz J
    Nucl Med Commun; 2001 Jun; 22(6):721-5. PubMed ID: 11403185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between clinical features of Parkinson's disease and presynaptic dopamine transporter binding assessed with [123I]IPT and single-photon emission tomography.
    Tatsch K; Schwarz J; Mozley PD; Linke R; Pogarell O; Oertel WH; Fieber RS; Hahn K; Kung HF
    Eur J Nucl Med; 1997 Apr; 24(4):415-21. PubMed ID: 9096093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.
    Booij J; Tissingh G; Boer GJ; Speelman JD; Stoof JC; Janssen AG; Wolters EC; van Royen EA
    J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):133-40. PubMed ID: 9048712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Striatal dopamine transporter binding assessed by [I-123]IPT and single photon emission computed tomography in patients with early Parkinson's disease: implications for a preclinical diagnosis.
    Schwarz J; Linke R; Kerner M; Mozley PD; Trenkwalder C; Gasser T; Tatsch K
    Arch Neurol; 2000 Feb; 57(2):205-8. PubMed ID: 10681078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential patterns of dopamine transporter loss in the basal ganglia of progressive supranuclear palsy and Parkinson's disease: analysis with [(123)I]IPT single photon emission computed tomography.
    Im JH; Chung SJ; Kim JS; Lee MC
    J Neurol Sci; 2006 May; 244(1-2):103-9. PubMed ID: 16473371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of alpha-dihydroergocryptine and levodopa monotherapy in Parkinson's disease: assessment of changes in DAT binding with [123I]IPT SPECT.
    Pöpperl G; Tatsch K; Ruzicka E; Storch A; Gasser T; Schwarz J
    J Neural Transm (Vienna); 2004 Aug; 111(8):1041-52. PubMed ID: 15254792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SPECT imaging of the dopamine transporter with [(123)I]-beta-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction.
    Sakakibara R; Shinotoh H; Uchiyama T; Yoshiyama M; Hattori T; Yamanishi T
    J Neurol Sci; 2001 Jun; 187(1-2):55-9. PubMed ID: 11440745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging and quantitation of dopamine transporters with iodine-123-IPT in normal and Parkinson's disease subjects.
    Kim HJ; Im JH; Yang SO; Moon DH; Ryu JS; Bong JK; Nam KP; Cheon JH; Lee MC; Lee HK
    J Nucl Med; 1997 Nov; 38(11):1703-11. PubMed ID: 9374337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.
    Tissingh G; Booij J; Bergmans P; Winogrodzka A; Janssen AG; van Royen EA; Stoof JC; Wolters EC
    J Nucl Med; 1998 Jul; 39(7):1143-8. PubMed ID: 9669384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [123I]IPT binding to the presynaptic dopamine transporter: variation of intra- and interobserver data evaluation in parkinsonian patients and controls.
    Linke R; Gostomzyk J; Hahn K; Tatsch K
    Eur J Nucl Med; 2000 Dec; 27(12):1809-12. PubMed ID: 11189944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism.
    Booij J; Speelman JD; Horstink MW; Wolters EC
    Eur J Nucl Med; 2001 Mar; 28(3):266-72. PubMed ID: 11315592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson's disease and controls.
    Eisensehr I; Linke R; Noachtar S; Schwarz J; Gildehaus FJ; Tatsch K
    Brain; 2000 Jun; 123 ( Pt 6)():1155-60. PubMed ID: 10825354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease.
    Leenders KL; Salmon EP; Tyrrell P; Perani D; Brooks DJ; Sager H; Jones T; Marsden CD; Frackowiak RS
    Arch Neurol; 1990 Dec; 47(12):1290-8. PubMed ID: 2123623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iodine-123-IPT SPECT imaging of CNS dopamine transporters: nonlinear effects of normal aging on striatal uptake values.
    Mozley PD; Kim HJ; Gur RC; Tatsch K; Muenz LR; McElgin WT; Kung MP; Mu M; Myers AM; Kung HF
    J Nucl Med; 1996 Dec; 37(12):1965-70. PubMed ID: 8970515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [123I]FPCIT SPECT.
    Booij J; Hemelaar TG; Speelman JD; de Bruin K; Janssen AG; van Royen EA
    J Nucl Med; 1999 May; 40(5):753-61. PubMed ID: 10319746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease.
    Lorberboym M; Treves TA; Melamed E; Lampl Y; Hellmann M; Djaldetti R
    Mov Disord; 2006 Apr; 21(4):510-4. PubMed ID: 16250023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Striatal dopamine transporter density decrease in first episode schizophrenic patients treated with risperidone].
    Mateos JJ; Lomeña F; Parellada E; Font M; Fernández E; Pavia J; Prats A; Bernardo M
    Rev Esp Med Nucl; 2006; 25(3):159-65. PubMed ID: 16762269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased striatal dopamine transporter binding assessed with [123I] FP-CIT in first-episode schizophrenic patients with and without short-term antipsychotic-induced parkinsonism.
    Mateos JJ; Lomeña F; Parellada E; Font M; Fernandez E; Pavia J; Prats A; Pons F; Bernardo M
    Psychopharmacology (Berl); 2005 Sep; 181(2):401-6. PubMed ID: 15830229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia.
    Jeon BS; Jeong JM; Park SS; Kim JM; Chang YS; Song HC; Kim KM; Yoon KY; Lee MC; Lee SB
    Ann Neurol; 1998 Jun; 43(6):792-800. PubMed ID: 9629849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.